Page 16 - Read Online

Cox et al. J Transl Genet Genom 2021;5:80-8 https://dx.doi.org/10.20517/jtgg.2021.06 Page 88

16. Wunderlich V. Early references to the mutational origin of cancer. Int J Epidemiol 2007;36:246-7. DOI PubMed
17. Dulbecco R. A turning point in cancer research: sequencing the human genome. Science 1986;231:1055-6. DOI PubMed
18. Yngvadottir B, Macarthur DG, Jin H, Tyler-Smith C. The promise and reality of personal genomics. Genome Biol 2009;10:237. DOI
PubMed PMC
19. Abecasis GR, Altshuler D, Auton A, et al; 1000 Genomes Project Consortium. A map of human genome variation from population-
scale sequencing. Nature 2010;467:1061-73. DOI PubMed PMC
20. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74. DOI PubMed
21. Fraietta JA, Lacey SF, Orlando EJ, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell
therapy of chronic lymphocytic leukemia. Nat Med 2018;24:563-71. DOI PubMed PMC
22. Deng Q, Han G, Puebla-Osorio N, et al. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and
toxicity in patients with large B cell lymphomas. Nat Med 2020;26:1878-87. DOI PubMed
23. Wright GW, Huang DW, Phelan JD, et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma
with therapeutic implications. Cancer Cell 2020;37:551-568.e14. DOI PubMed
24. Sheih A, Voillet V, Hanafi LA, et al. Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing
CD19 CAR-T immunotherapy. Nat Commun 2020;11:219. DOI PubMed PMC
25. Manriquez-Roman C, Siegler EL, Kenderian SS. CRISPR takes the front seat in CART-cell development. BioDrugs 2021;35:113-24.
DOI PubMed
26. Wang W, Fasolino M, Cattau B, et al. Joint profiling of chromatin accessibility and CAR-T integration site analysis at population and
single-cell levels. Proc Natl Acad Sci U S A 2020;117:5442-52. DOI PubMed PMC
27. Gomes-Silva D, Mukherjee M, Srinivasan M, et al. Tonic 4-1BB costimulation in chimeric antigen receptors impedes T cell survival
and is vector-dependent. Cell Rep 2017;21:17-26. DOI PubMed PMC
28. Long AH, Haso WM, Shern JF, et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric
antigen receptors. Nat Med 2015;21:581-90. DOI PubMed PMC
29. Sterner RM, Sakemura R, Cox MJ, et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances
CAR-T cell function in xenografts. Blood 2019;133:697-709. DOI PubMed PMC
30. Parker KR, Migliorini D, Perkey E, et al. Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets
for CAR-T immunotherapies. Cell 2020;183:126-142.e17. DOI PubMed PMC
31. Cox MJ, Lucien F, Sakemura R, et al. Leukemic extracellular vesicles induce chimeric antigen receptor T cell dysfunction in chronic
lymphocytic leukemia. Mol Ther 2021;29:1529-40. DOI PubMed PMC
32. Sakemura R, Cox MJ, Hansen MJ, et al. Targeting cancer associated fibroblasts in the bone marrow prevents resistance to chimeric
antigen receptor T cell therapy in multiple myeloma. Blood 2019;134:865. DOI
33. Cassetta L, Fragkogianni S, Sims AH, et al. Human tumor-associated macrophage and monocyte transcriptional landscapes reveal
cancer-specific reprogramming, biomarkers, and therapeutic targets. Cancer Cell 2019;35:588-602.e10. DOI PubMed PMC
34. Jain MD, Faramand R, Staedtke V, et al. The lymphoma tumor microenvironment influences toxicity after CD19 CAR T cell therapy.
Blood 2019;134:4105. DOI
35. Jain MD, Zhao H, Atkins R, et al. Tumor inflammation and myeloid derived suppressor cells reduce the efficacy of CD19 CAR T cell
therapy in lymphoma. Blood 2019;134:2885. DOI
36. Lee HW, Chung W, Lee HO, et al. Single-cell RNA sequencing reveals the tumor microenvironment and facilitates strategic choices to
circumvent treatment failure in a chemorefractory bladder cancer patient. Genome Med 2020;12:47. DOI PubMed PMC
37. Cooper ZA, Frederick DT, Juneja VR, et al. BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes.
Oncoimmunology 2013;2:e26615. DOI PubMed PMC
38. Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours
treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet
Oncol 2020;21:1353-65. DOI PubMed
39. Majzner RG, Mackall CL. Tumor antigen escape from CAR T-cell therapy. Cancer Discov 2018;8:1219-26. DOI PubMed
40. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med
2014;371:1507-17. DOI PubMed PMC
41. Sotillo E, Barrett DM, Black KL, et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to
CART-19 immunotherapy. Cancer Discov 2015;5:1282-95. DOI PubMed PMC
42. Barash Y, Vaquero-Garcia J, González-Vallinas J, et al. AVISPA: a web tool for the prediction and analysis of alternative splicing.
Genome Biol 2013;14:R114. DOI PubMed PMC
43. Singh N, Lee YG, Shestova O, et al. impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing
CAR T-cell dysfunction. Cancer Discov 2020;10:552-67. DOI PubMed PMC